Skip to main content
ISLAND PHARMACEUTICALS LIMITED logo

ISLAND PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · ILA ISIN · AU0000138869 LEI · 5299007AAXFWP52UC792 ASX Professional, scientific and technical activities
Open in API
Filings indexed 399 across all filing types
Latest filing 2026-05-20 Board/Management Inform…
Country AU Australia
Listing ASX ILA

About ISLAND PHARMACEUTICALS LIMITED

https://www.islandpharmaceuticals.com

Island Pharmaceuticals Limited is a clinical-stage drug repurposing company focused on developing preventative and therapeutic countermeasures for infectious diseases. The company specializes in identifying and advancing existing drug candidates to address high-priority viral threats, particularly mosquito-borne diseases. Its lead program, ISLA-101, is a small molecule drug being repurposed as a potential preventative and therapeutic treatment for Dengue fever. By leveraging the drug repurposing model, the company aims to reduce the time, cost, and risk associated with traditional drug development. Island Pharmaceuticals targets global health challenges where there are currently no approved vaccines or effective antiviral treatments, focusing on rapid clinical advancement to meet significant unmet medical needs in tropical and emerging infectious diseases.

Recent filings

Filing Released Lang Actions
Island Adds Biodefence Leader as Filovirus Risks Escalate 6 pages 221.3KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement announcing the appointment of a new Senior Scientific Fellow (Mr Raymond Taylor). It is a management change/appointment notice rather than a financial or regulatory report. Therefore, it fits the ‘Board/Management Information’ category.
2026-05-20 English
Island Bolsters US Biodefence Readiness Ahead of Trials 4 pages 161.4KB
Board/Management Information Classification · 88% confidence The document is an ASX announcement detailing the appointment of Mark Herzog as Senior Global Health Security Advisor and related senior management engagement initiatives. This is a clear announcement of a change/addition to senior management, matching the Board/Management Information category.
2026-05-18 English
Application for quotation of securities - ILA 6 pages 18.3KB
Share Issue/Capital Change Classification · 94% confidence The document is an ASX Appendix 2A “Application for quotation of securities,” detailing the issuance and quotation of 335,000 new ordinary shares upon exercise of options. This is a direct announcement of a share issue/capital change under ASX Listing Rules. It does not present full financials (so not an Annual or Interim Report), nor is it a dividend, management change, or other category. It falls squarely under announcements of new share issues and capital structure changes (Share Issue/Capital Change).
2026-04-27 English
Cleansing Notice 1 page 159.6KB
Share Issue/Capital Change Classification · 90% confidence The document is a cleansing notice under section 708A of the Corporations Act regarding the issue of 335,000 shares upon exercise of unlisted options. It is an announcement of a share issuance, fitting the “Share Issue/Capital Change” category, code SHA.
2026-04-27 English
Quarterly Appendix 4C and Activities Report 11 pages 419.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'March 2026 Quarterly Activities Report' and is issued by Island Pharmaceuticals. It provides a detailed summary of operational, clinical, and corporate activities for the three-month period ended 31 March 2026. It includes management commentary, operational overviews, and financial updates (such as capital raising and R&D tax incentives). As it covers a period shorter than a full fiscal year and contains substantive analysis of company activities and financial status, it fits the definition of an Interim/Quarterly Report. Q3 2026
2026-04-26 English
Application for quotation of securities - ILA 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement from Island Pharmaceuticals Limited regarding the application for quotation of securities on the ASX. It details the issuance and conversion of options into ordinary fully paid shares, the number of securities to be quoted, issue price, and other related information. This type of document is a formal announcement related to new securities being issued and quoted on the exchange, which corresponds to a Share Issue/Capital Change announcement. It is not a full financial report, earnings release, or management discussion, but a regulatory announcement about capital changes.
2026-03-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.